PROSTATE CANCER CELL PROLIFERATION IN STRONGLY REDUCED BY COMBINATION OF TREATMENT WITH THE EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR ZD1839 (“IRESSA”) AND THE ANTIANDROGEN BICALUTAMIDE (“CASODEX”)